P2 purinergic receptor expression and function in tumor-related immune cells.

IF 3 4区医学 Q2 NEUROSCIENCES

Purinergic Signalling Pub Date : 2024-10-10 DOI:10.1007/s11302-024-10054-7

Vahinipriya Manoharan, Oluwafemi O Adegbayi, Janielle P Maynard

{"title":"P2 purinergic receptor expression and function in tumor-related immune cells.","authors":"Vahinipriya Manoharan, Oluwafemi O Adegbayi, Janielle P Maynard","doi":"10.1007/s11302-024-10054-7","DOIUrl":null,"url":null,"abstract":"<p><p>P2 purinergic receptor expression is dysregulated in multiple cancer subtypes and is associated with worse outcomes. Studies identify roles for P2 purinergic receptors in tumor cells that drive disease aggressiveness. There is also sufficient evidence that P2 purinergic receptor expression within the tumor microenvironment (TME) is critical for disease initiation and progression. Immune cells constitute a significant component of the TME and display both tumorigenic and anti-tumorigenic potential. Studies pre-dating the investigation of P2 purinergic receptors in cancer identify P2 receptor expression on multiple immune cells including macrophages, neutrophils, T-cells, and dendritic cells; all of which are implicated in tumor initiation, tumor promotion, or response to treatment. Herein, we discuss P2 purinergic receptor expression and function in tumor-related immune cells. We provide a rationale for further investigations of P2 purinergic receptors within the TME to better define the mechanistic pathways of inflammation-mediate tumorigenesis and explore P2 purinergic receptors as potential targets for novel immunotherapeutic approaches.</p>","PeriodicalId":20952,"journal":{"name":"Purinergic Signalling","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Purinergic Signalling","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11302-024-10054-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

P2 purinergic receptor expression is dysregulated in multiple cancer subtypes and is associated with worse outcomes. Studies identify roles for P2 purinergic receptors in tumor cells that drive disease aggressiveness. There is also sufficient evidence that P2 purinergic receptor expression within the tumor microenvironment (TME) is critical for disease initiation and progression. Immune cells constitute a significant component of the TME and display both tumorigenic and anti-tumorigenic potential. Studies pre-dating the investigation of P2 purinergic receptors in cancer identify P2 receptor expression on multiple immune cells including macrophages, neutrophils, T-cells, and dendritic cells; all of which are implicated in tumor initiation, tumor promotion, or response to treatment. Herein, we discuss P2 purinergic receptor expression and function in tumor-related immune cells. We provide a rationale for further investigations of P2 purinergic receptors within the TME to better define the mechanistic pathways of inflammation-mediate tumorigenesis and explore P2 purinergic receptors as potential targets for novel immunotherapeutic approaches.

查看原文本刊更多论文

肿瘤相关免疫细胞中 P2 嘌呤能受体的表达和功能。

P2 嘌呤能受体在多种癌症亚型中表达失调，并与恶化的预后有关。研究发现，P2嘌呤能受体在肿瘤细胞中起着驱动疾病侵袭性的作用。还有充分证据表明，P2嘌呤能受体在肿瘤微环境（TME）中的表达对疾病的发生和发展至关重要。免疫细胞是肿瘤微环境的重要组成部分，具有致瘤和抗肿瘤的潜能。在对癌症中的 P2 嘌呤能受体进行调查之前的研究发现，多种免疫细胞（包括巨噬细胞、中性粒细胞、T 细胞和树突状细胞）上都有 P2 受体的表达；所有这些细胞都与肿瘤的诱发、肿瘤的促进或对治疗的反应有关。在此，我们将讨论 P2 嘌呤能受体在肿瘤相关免疫细胞中的表达和功能。我们为进一步研究 TME 中的 P2 嘌呤能受体提供了理论依据，以更好地界定炎症介导肿瘤发生的机理途径，并探索 P2 嘌呤能受体作为新型免疫治疗方法潜在靶点的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Purinergic Signalling 医学-神经科学

CiteScore

6.60

自引率

17.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.